menu
    • menu
    [{"orgOrder":0,"company":"Insulet Corporation","sponsor":"Bigfoot Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Acquisition","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Insulet Corporation","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Insulet Corporation \/ Insulet Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Insulet Corporation \/ Insulet Corporation"},{"orgOrder":0,"company":"Insulet Corporation","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2015","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Insulet Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Insulet Corporation \/ Insulet Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Insulet Corporation \/ Insulet Corporation"},{"orgOrder":0,"company":"Insulet Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Insulet Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Insulet Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Insulet Corporation \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Insulet Corporation

    Menu

    Insulet Corporation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Insulet Corporation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Insulet Corporation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Insulet Reveals FDA Clearance of Omnipod® 5 Algorithm Enhancements for Insulin Delivery

                            Details : Insulin, a hormone targeting the insulin receptor, shows promising development in treating Diabetes Mellitus.

                            Product Name : Omnipod 5

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            December 04, 2025

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Insulet Corporation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Insulet Corporation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Recipient : Bigfoot Biomedical

                            Deal Size : $25.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Insulet Acquires Insulin Pump Patents from Bigfoot Biomedical as Both Companies Prioritize Improved Insulin De...

                            Details : Insulet’s latest innovation, the Omnipod® 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections and zero fingersticks.

                            Product Name : Omnipod

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            February 13, 2023

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Recipient : Bigfoot Biomedical

                            Deal Size : $25.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Insulet Corporation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Insulet Corporation

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Recipient : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes ...

                            Details : Insulin is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            September 25, 2015

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Recipient : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth